Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

haha1978 Jan. 29 at 8:21 PM

$TCGL $CPIX Wow TCGL has the same shares outstanding and a very similar float to CPIX. Gives me hope the difference is the 16% short position in the stock. Hope the shorts get wiped out. Good luck Longs I think you did great.

0 · Reply

BioResearcher Jan. 29 at 4:42 PM

$CPIX General market is crashing today.... Thanks for Microsoft. :-)

0 · Reply

BioResearcher Jan. 29 at 4:11 AM

$CPIX If Management decides to PR the recent breakthrough TNBC finding, this stock will be in double digits ! Wait for it !

1 · Reply

haha1978 Jan. 29 at 2:38 AM

$CPIX management never mentioned this study imo to surprise the market. Fingers crossed.

1 · Reply

haha1978 Jan. 29 at 2:27 AM

$CPIX Hopefully CPIX can partner with a BP for a P3 study if the results from the P2 is good for cancer metastasis prevention.

1 · Reply

haha1978 Jan. 29 at 2:19 AM

$CPIX well its only a 30 patient double blind p2 cancer metastasis study over 6 years. We will probably get the results in the next 3 months. I hope its true. They completed the study 4/2025.

0 · Reply

haha1978 Jan. 29 at 2:07 AM

$CPIX https://clinicaltrials.gov/study/NCT03694249?tab=study&a=15 If you read it looks like this ifetroban P2 study to treat cancer metasis will be completed 4/2026. Its a 6 year study. Or is this just an mistake? Im going to email the investigator at Vanderbilt.

0 · Reply

BioResearcher Jan. 28 at 9:04 PM

$CPIX Heavy volume today ! 260K shares on a nasty biotech day ! Be patient, folks....

0 · Reply

BioResearcher Jan. 28 at 8:53 PM

$CPIX To have a 20 folds gain stock is to get in early, where the potential is only known to a few, and no analysts pump. when it is invisible to Wall Street. CPIX fits my screening criteria.

0 · Reply

BioResearcher Jan. 28 at 7:21 PM

$CPIX This is just a small number of recent examples of Big pharm buying out promising preclinic can drugs:

0 · Reply

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 3 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 3 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 3 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 4 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 1:52 AM EDT - 6 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 6 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 6 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 7 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 8 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 9 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 9 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 9 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 9 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 11 months ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 11 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 11 months ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 1 year ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

haha1978 Jan. 29 at 8:21 PM

0 · Reply

BioResearcher Jan. 29 at 4:42 PM

$CPIX General market is crashing today.... Thanks for Microsoft. :-)

0 · Reply

BioResearcher Jan. 29 at 4:11 AM

$CPIX If Management decides to PR the recent breakthrough TNBC finding, this stock will be in double digits ! Wait for it !

1 · Reply

haha1978 Jan. 29 at 2:38 AM

$CPIX management never mentioned this study imo to surprise the market. Fingers crossed.

1 · Reply

haha1978 Jan. 29 at 2:27 AM

$CPIX Hopefully CPIX can partner with a BP for a P3 study if the results from the P2 is good for cancer metastasis prevention.

1 · Reply

haha1978 Jan. 29 at 2:19 AM

$CPIX well its only a 30 patient double blind p2 cancer metastasis study over 6 years. We will probably get the results in the next 3 months. I hope its true. They completed the study 4/2025.

0 · Reply

haha1978 Jan. 29 at 2:07 AM

0 · Reply

BioResearcher Jan. 28 at 9:04 PM

$CPIX Heavy volume today ! 260K shares on a nasty biotech day ! Be patient, folks....

0 · Reply

BioResearcher Jan. 28 at 8:53 PM

$CPIX To have a 20 folds gain stock is to get in early, where the potential is only known to a few, and no analysts pump. when it is invisible to Wall Street. CPIX fits my screening criteria.

0 · Reply

BioResearcher Jan. 28 at 7:21 PM

$CPIX This is just a small number of recent examples of Big pharm buying out promising preclinic can drugs:

0 · Reply

BioResearcher Jan. 28 at 6:07 PM

$CPIX This cancer market size is too big for big pharma to ignore. That is why big pharm love to buy any drug that has shown great efficacy in Preclinic settings. In case of Ifetroban, not only it has shown impressive efficacy, it has proven safe in human trials.

0 · Reply

BioResearcher Jan. 28 at 4:29 PM

$CPIX Ifetroban in cancer indication alone is targeting a $100+ billions treatment market !!! "The global metastatic cancer drugs market, valued between $67.7 billion and $108.1 billion in 2022–2023, is projected to reach over $136 billion to $168 billion by 2029–2032, with a CAGR ranging from 6% to 7.7%

0 · Reply

BioResearcher Jan. 28 at 4:00 PM

$CPIX Keep in mind that the Ifetroban 's breakthrough finding on TNBC treatment has been peer-reviewed and published on an well-known cancer journal. Also the study was from 2 universities that is independent of the Company. Those facts validate the integrity of the dataset. Big pharm will take notice.

0 · Reply

BioResearcher Jan. 28 at 2:41 PM

$CPIX I have never seen any drugs that has this impressive result for the most deadly cancer TNBC before: "The study showed ifetroban reduced lung metastases by 67%, liver metastases by 60% in animal models and reduced overall circulating tumor cells by more than 50%." This data has been presented in the largest Breast Cancer International Conference last month, Many big pharm were there in the Conference, Either BO or partnerships are likely to come soon. Stay tuned...

1 · Reply

haha1978 Jan. 28 at 1:48 AM

$CPIX inverted hammer is the same or better than a spinning top. We have a 65% chance of reversal probably after the fed decision.

0 · Reply

BioResearcher Jan. 27 at 1:19 PM

$CPIX The impatient small investors are selling. But the near and long term potential of CPIX have not changed. The recent breakthrough of Ifetroban on TNBC would make CPIX a prime takeover target.

1 · Reply

BioResearcher Jan. 26 at 9:15 PM

$CPIX It seems like it is slowly drift back to $2 ... oh, well.. Management is just too quiet...

3 · Reply

BioResearcher Jan. 25 at 7:10 PM

$CPIX There are currently only 2 approved drugs for IPF, but they have terrible side effects. (Ifetroban has only minor side effects)

0 · Reply

haha1978 Jan. 25 at 5:05 PM

$CPIX cost vary but the original pirfenidone treatment are 11000 dollars a month. Ifetroban could easily be 130k a year and more effective. Generics are 400 to 2500 a month.

1 · Reply

haha1978 Jan. 25 at 8:23 AM

$CPIX another use for ifetroban to prevent stiffness of the heart or fibrosis of the heart for cancer drug that damages the heart in specific cases. https://solutions.tufts.edu/expertise/infection-immunity/why-most-prescribed-chemotherapy-drug-can-cause-serious-heart-damage

1 · Reply

haha1978 Jan. 24 at 2:32 AM

$CPIX bnai gives me hope for cpix. Will maintain my large position all year. Ifetroban can really light this up.

1 · Reply

haha1978 Jan. 24 at 1:53 AM

$CPIX $BNAI congratulations BNAI traders. Exceptional nanocap squeeze. Cpix has a 5 million float subtracting the ceo 45% stake and institutions 25% stake. They have an Ideopathic Pulmonary fibrosis p2 study coming out with AI analysis that could blow the stock up similarly if good data is released. Total shares are 15 million outstanding. They also have 40 to 50 million in annual revenue from 7 approved FDA drugs. Look up their drug ifetroban development and the cancer animal study that stopped cancer from spreading which kills 90% of people. $XBI

1 · Reply

Market Cap	57.29M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	46.75
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.20

Volume	95,300
Avg Vol	194,472
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	7%
Beta	-0.53
Analysts	Strong Buy
Price Target	$8.50